Citations

Clear

415 citation(s) found for "Snyder, M".

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, Clifford R. , Andrews, J. Scott , Beach, Thomas G. , Buracchio, Teresa , Dunn, Billy , Graf, Ana, Ho, Carole , Jagust, William J. , Okonkwo, Ozioma C. , Siemers, Eric , Snyder, Heather M. , Carrillo, Marı́a C., Carrillo, María C. , Jack, Clifford R , Hansson, Oskar , McDade, Eric , Molinuevo, José Luís , Pani, Luca , Rafii, Michael S. , Scheltens, Philip , Sperling, Reisa Anne , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 27, 2024 | Volume: 20 | Issue: 8 | Pages: 5143-5169

10.1002/alz.13859 | PMID 38934362 Get It

Abstract The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD, incorporating recent advances in biomarkers, to serve as a bridge between research and clinical care. These criteria are not intended to provide step‐by‐step clinical practice guidelines for clinical workflow or specific treatment protocols, but rather serve as general principles to inform diagnosis and staging of AD that reflect current science. Highlights We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms. Early‐changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway; however, these reflect the presence of ADNPC more generally (i.e., both neuritic plaques and tangles). An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum. Later‐changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms. An integrated biological and clinical staging scheme is described that accommodates the fact that common copathologies, cognitive reserve, and resistance may modify relationships between clinical and biological AD stages.
Association of Chemotherapy-Induced Peripheral Neuropathy with Diet Quality Among Post-Treatment Cancer Survivors
Knoerl, Robert , Ploutz‐Snyder, Robert , Smener, Liat, Tofthagen, Cindy , Zick, Suzanna M. , Tofthagen, Cindy S

Mayo Clinic

Nutrition and Cancer | June 26, 2024 | Volume: 76 | Issue: 8 | Pages: 717-725

10.1080/01635581.2024.2364389 | PMID 38919034 Get It

Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine ( NABPLAGEM ) in patients with untreated advanced pancreatic cancer
Jameson, Gayle , Hosein, Peter J. , Pierce, Erin, Kamgar, Mandana , Snyder, Courtney, Roe, Denise J. , Wertheim, Betsy C. , Davey, M., Barrett, Michael T. , Hoff, Daniel D. Von , Borazanci, Erkut , Borazanci, Erkut , Jameson, Gayle S , Gordon, Michael S.

Mayo Clinic

Cancer Medicine | June 22, 2024 | Volume: 13 | Issue: 12 | Pages: No page available

10.1002/cam4.7412 Get It

Abstract Background A previous phase IB/II study of nab‐paclitaxel + cisplatin + gemcitabine (NABPLAGEM) in 25 patients with previously untreated metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrated favorable results. This phase II study was conducted to further evaluate the safety, efficacy, and impact on quality of life (QOL) of NABPLAGEM in a multi‐center setting. Methods Participants were ≥18 years; had measurable PDAC; Karnofsky performance status of ≥70%; life expectancy ≥12 weeks; <grade 2 pre‐existing peripheral neuropathy, and adequate hematologic, hepatic, and renal function. Study treatment included nab‐paclitaxel (125 mg/m 2 ), cisplatin (25 mg/m 2 ), and gemcitabine (1000 mg/m 2 ), on Days 1 and 8 of a 21‐day cycle. The primary endpoint was 12‐month overall survival (OS). Results A total of 42 patients were enrolled with a median age of 66.8 years, a majority were male (66.7%) and white (76.2%). Treatment‐related adverse events ≥grade 3 were: thrombocytopenia (64.3%), anemia (47.6%), and neutropenia (26.1%). OS at 12 months was 38.1%, with 12% of patients alive as of last contact (20–40+ months). In 37 evaluable participants responses included: partial response (40.5%), stable disease (43.2%), and progressive disease (16.2%), with overall response rate of 40.5% and DCR of 88.6%. Statistically significant improvement in QOL was reported during the first three cycles. Conclusion The primary objective of achieving a 12‐month survival comparable to the previous phase Ib/II NABPLAGEM PCRT 12‐001 was not achieved in this trial. NABPLAGEM has efficacy in advanced PDAC, demonstrating early disease control noted by improvement in patient symptoms, decrease in tumor volume and tumor markers within the first 9 weeks. The activity and tolerability make this a suitable regimen for further testing in the neoadjuvant setting.
Single cell multiomic analyses reveal divergent effects of DNMT3A and TET2 mutant clonal hematopoiesis in inflammatory response
Binder, Moritz , Lasho, Terra, Geyer, Susan M. , Finke, Christy M. , Mangaonkar, Abhishek A. , Simon, Vernadette, Rohakthar, Fariborz Rakhshan, Munankarmy, Amik, Schwager, Susan M., Harrington, Jonathan J. , Snyder, Melissa R. , Wieben, Eric D. , Patnaik, Mrinal M. , Binder, Moritz , Ismail, Wazim Mohammed , Fernandez, Jenna , Kim, Minsuk , Mazzone, Amelia , Lee, Jeong‐Heon , Wang, Liguo , Kim, Kwan‐Hyun , Munankarmy, Amik , Byeon, Seul Kee , Robertson, Keith D. , Pandey, Akhilesh , Chia, Nicholas , Gaspar‐Maia, Alexandre

Mayo Clinic

No container title available | June 13, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4481664/v1 Get It

Abstract Background DNMT3A and TET2 are epigenetic regulator genes commonly mutated in age-related clonal hematopoiesis (CH). Despite having opposing epigenetic functions, these mutations are associated with increased all-cause mortality and a low risk for progression to hematological neoplasms. While individual impacts on the epigenome have been described using different model systems, the phenotypic complexity in humans remains to be elucidated. Results Here we make use of a natural inflammatory response occurring during coronavirus disease 2019 (COVID-19), to understand the association of these mutations with inflammatory morbidity and mortality. We demonstrate the age-independent, negative impact of DNMT3A mutant CH on COVID-19-related cytokine release severity and mortality. Using single cell proteogenomics we show that DNMT3A mutations involve myeloid and lymphoid cells. Using single cell multiomics sequencing, we identify cell-specific gene expression changes associated with DNMT3A mutations, along with significant epigenomic deregulation affecting enhancer accessibility, resulting in overexpression of IL32, a proinflammatory cytokine that can result in inflammasome activation in monocytes and macrophages. Finally, we show with single cell resolution that the loss of function of DNMT3A is directly associated with increased chromatin accessibility in mutant cells. Conclusions We demonstrate the negative prognostic impact of DNMT3Amt CH on COVID-19 related inflammatory morbidity and mortality. DNMT3Amt CH involves myeloid and lymphoid cells and in the context of COVID-19, was associated with inflammatory transcriptional priming, resulting in overexpression of IL32. This overexpression was secondary to increased chromatic accessibility, specific to DNMT3Amt CH cells. DNMT3Amt CH can serve as a potential biomarker for adverse inflammatory outcomes.
Pro Inflammatory Cytokines Profiles of Patients With Long COVID Differ Between Variant Epochs
Ganesh, Ravindra , Yadav, Siddhant, Mueller, Michael , Aakre, Christopher A. , Gilman, Elizabeth A. , Grach, Stephanie L. , Overgaard, Joshua , Snyder, Melissa R. , Collins, Nerissa M. , Croghan, Ivana T. , Salonen, Bradley R. , Hurt, Ryan T. , Grach, Stephanie L , Croghan, Ivana T , Ganesh, Ravindra , Badley, Andrew D. , Razonable, Raymund R.

Mayo Clinic

Journal of Primary Care & Community Health | May 29, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241254751 | PMID 38808863 Get It

Background: Over 30% of patients with COVID-19 have persistent symptoms that last beyond 30 days and referred to as Long COVID. Long COVID has been associated with a persistent elevation in peripheral cytokines including interleukin-6, interleukin-1β, and tumor necrosis factor-α. This study reports cytokine profiles of patients in our clinic across SARS-COV-2 variant epochs. Methods: The clinical cytokine panel was analyzed in patients with Long COVID during periods that were stratified according to variant epoch. The 4 variant epochs were defined as: (1) wild-type through alpha, (2) alpha/beta/gamma, (3) delta, and (4) omicron variants. Results: A total of 390 patients had the clinical cytokine panel performed; the median age was 48 years (IQR 38-59) and 62% were female. Distribution by variant was wild-type and alpha, 50% (n = 196); alpha/beta/gamma, 7.9% (n = 31); delta, 18% (n = 72); and omicron, 23% (n = 91). Time to cytokine panel testing was significantly longer for the earlier epochs. Tumor necrosis factor-α ( P < .001) and interleukin 1β ( P < .001) were significantly more elevated in the earlier epochs (median of 558 days in wild-type through Alpha epoch vs 263 days in omicron epoch, P < .001)). Nucleocapsid antibodies were consistently detected across epochs. Discussion: When stratified by variant epoch, patients with early epoch Long COVID had persistently elevated peripheral pro-inflammatory cytokine levels when compared to later epoch Long COVID. Patients with Long COVID have similar clusters of symptoms across epochs, suggesting that the underlying pathology is independent of the peripheral cytokine signature.
Methods for building a staff workforce of quantitative scientists in academic health care
Peskoe, Sarah B. , Slade, Emily , Rende, Lacey , Boulos, Mary , Desai, Manisha , Gandhi, Mihir , Gelfond, Jonathan , Khalatbari, Shokoufeh , Schulte, Phillip J. , Taylor, Sandra L. , Peskoe, Sarah , Troy, Jesse D , Pomann, Gina-Maria , Desai, Manisha , Snyder, Denise Clutter , Vaughan, Roger

Mayo Clinic

Stat | May 6, 2024 | Volume: 13 | Issue: 2 | Pages: No page available

10.1002/sta4.683 | PMID 39176389 Get It

Collaborative quantitative scientists, including biostatisticians, epidemiologists, bioinformaticists, and data‐related professionals, play vital roles in research, from study design to data analysis and dissemination. It is imperative that academic health care centers (AHCs) establish an environment that provides opportunities for the quantitative scientists who are hired as staff to develop and advance their careers. With the rapid growth of clinical and translational research, AHCs are charged with establishing organizational methods, training tools, best practices, and guidelines to accelerate and support hiring, training, and retaining this staff workforce. This paper describes three essential elements for building and maintaining a successful unit of collaborative staff quantitative scientists in academic health care centers: (1) organizational infrastructure and management, (2) recruitment, and (3) career development and retention. Specific strategies are provided as examples of how AHCs can excel in these areas.
Abstract 18573: Genetic Variation of the Alpha-Subunit of the Epithelial Sodium Channel Influences the Lung Fluid Response to Hypoxia in Healthy Humans
Wheatley, Courtney M. , Johnson, Bruce , Snyder, Eric M. , Baker, Sarah E. , Taylor, Bryan J. , Keller‐Ross, Manda L. , Johnson, Bruce, Snyder, Eric M

Mayo Clinic

Circulation | April 23, 2024 | Volume: 128 | Issue: suppl_22 | Pages: No page available

10.1161/circ.128.suppl_22.a18573 Get It

Cardiogenic pulmonary edema is a life-threatening complication in patients with heart failure (HF) resulting from increased alveolar Cl- secretion and inhibition of alveolar epithelial Na+ channels (ENaC). Not all HF patients develop pulmonary edema, despite similar clinical characteristics, suggesting a genetic component to edema formation in response to cardiac failure. The ENaC are crucial for alveolar fluid clearance, with the alpha subunit demonstrating particular importance. We have previously found that genetic variation of the alpha subunit (SCNN1A) of ENaC, an alanine (A) to threonine (T) substitution, influences ion regulation during exercise and in response to albuterol. In the present study, we sought to determine the influence of the threonine variant (T663; AT/TT group) on lung fluid regulation in response to normobaric hypoxia, an environmental condition known to increase pulmonary capillary hydrostatic stress in healthy humans. Lung ion and fluid changes were assessed using exhaled Na+ (ENa+) and the lung diffusing capacity for carbon monoxide and nitric oxide (DLCO and DLNO, respectively) to determine alveolar-capillary membrane conductance (DM). 19 healthy subjects (n=8 vs. 11, %female=50 vs. 62%, age=27±1 vs. 28±2yrs., ht=171±3 vs. 173±2cm, wt=69±6 vs.72±3kg , BMI=23±1 vs.24±1kg/m2 , for AA and AT/TT, respectively) completed two overnight visits in a hypoxic tent simulating just over 5,400m. The visits were randomized to inhaled placebo (P) or inhaled amiloride (Aml, 1.5mg in 5ml normal saline, used to inhibit ENaC activity) with ENa+, DLCO, and DM assessed at baseline and following 12 hours of hypoxic exposure. There was an effect of genotype on the ENa+ response to hypoxia with placebo that was abolished with amiloride, but no effect of genotype on the diffusing capacity of the lung (Table). These results suggest that genetic variation of SCNN1A may influence ion regulation in the lung under conditions of elevated hydrostatic stress.
Mind the Gap! Working Toward Gender Equity in Pediatric and Congenital Heart Disease: Present and Future
Chowdhury, Devyani , Bansal, Neha , Ansong, Annette , Baker‐Smith, Carissa M. , Choueiter, Nadine , Co‐Vu, Jennifer , Elliott, Pietro , Fuller, Stephanie , Jain, Supriya , Johnson, Jonathan N. , Karamlou, Tara , Kipps, Alaina K. , Laraja, Kristin, Rasheed, Muneera A. , Ronai, Christina , Sachdeva, Ritu , Snyder, Christopher S. , Sutton, Nicole , Stiver, Corey, Shaffer, Kenneth M. , Williams, Roberta G. , Baker-Smith, Carissa M , Co-Vu, Jennifer , Elliott, Pietro , Fuller, Stephanie , Jain, Supriya S , Jone, Pei-Ni , Johnson, Jonathan , Kipps, Alaina K , Lopez, Keila N , Rasheed, Muneera , Ronai, Christina , Sachdeva, Ritu , Snyder, Chris , Sutton, Nicole , Taggart, Nathaniel W , Shaffer, Kenneth , Williams, Roberta , Bauser‐Heaton, Holly , Lopez, Keila N. , Saidi, Arwa S. , Taggart, Nathaniel W.

Mayo Clinic

Journal of the American Heart Association | April 19, 2024 | Volume: 13 | Issue: 9 | Pages: No page available

10.1161/jaha.123.032837 | PMID 38639355 Get It

Evidence from medicine and other fields has shown that gender diversity results in better decision making and outcomes. The incoming workforce of congenital heart specialists (especially in pediatric cardiology) appears to be more gender balanced, but past studies have shown many inequities. Gender‐associated differences in leadership positions, opportunities presented for academic advancement, and recognition for academic contributions to the field persist. In addition, compensation packages remain disparate if evaluated based on gender with equivalent experience and expertise. This review explores these inequities and has suggested individual and institutional changes that could be made to recruit and retain women, monitor the climate of the institution, and identify and eliminate bias in areas like salary and promotions.
Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration
Staffaroni, Adam M. , Clark, Annie L , Taylor, Jack C. , Heuer, Hilary W. , Wise, Amy B. , Dhanam, Sreya , Wolf, Amy , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rankin, Katherine P. , Clark, David , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Masdeu, Joseph C. , Massimo, Lauren , Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Rascovsky, Katya, Roberson, Erik D. , Wong, Bonnie , Kornak, John , Kremers, Walter K. , Hassenstab, Jason , Kramer, Joel H. , Rosen, Howard J. , Boxer, Adam L. , Apostolova, Liana G. , Barmada, Sami J. , Brushaber, Danielle , Day, Gregg S, Dickerson, Bradford, Faber, Kelley, Fagan, Anne M. , Foroud, Tatiana M., Gavrilova, Ralitza H. , Graff‐Radford, Jonathan , Grant, Ian , Hall, Matthew , Hales, Chadwick M. , Huang, Eric J. , Johnson, Noah R. , Kolander, Tyler, Kwan, Justin , Lago, Argentina Lario , Lavigne, Shannon B., Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , McGinnis, Scott, Molden, Joie, Naasan, Georges , Onyike, Chiadi U. , Petrucelli, Leonard , Rademakers, Rosa , Rao, Meghana , Rhoads, Kristoffer , Ritter, Aaron, Rogalskı, Emily , Savica, Rodolfo , Sullivan, Anne C. , Syrjanen, Jeremy M., Weıntraub, Sandra , Wint, Dylan , Yokoyoma, Jennifer, Roberson, Erik , Pascual, Belen , Hassenstab, Jason , Kremers, Walter K , Domoto-Reilly, Kimiko , Barmada, Sami , Sanderson‐Cimino, Mark , Cobigo, Yann , Appleby, Brian S. , Bayram, Ece , Bozoki, Andrea C , Galasko, Douglas , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Jones, David T. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Ramanan, Vijay K. , Tartaglia, Maria Carmela , Miller, Bruce L. , Boeve, Bradley F. , Botha, Hugo , Day, Gregg S, Dickson, Dennis W. , Elahi, Fanny M. , Fong, Jamie , Gendron, Tania F. , Goldman, Jill , Honig, Lawrence S. , Irwin, David J. , Johnson, Noah, Kantarci, Kejal , Knopman, David S. , Léger, Gabriel C. , McMillan, Corey T. , Pantelyat, Alexander , Paolillo, Emily W. , Paulson, Henry L. , Rexach, Jessica E. , Rojas, Julio C. , Seeley, William W. , Snyder, Allison , Sullivan, Anne C., Tipton, Philip W. , Vandebergh, Marijne , Toga, Arthur W. , VandeVrede, Lawren , Wszołek, Zbigniew K.

Mayo Clinic

JAMA Network Open | April 1, 2024 | Volume: 7 | Issue: 4 | Pages: e244266

10.1001/jamanetworkopen.2024.4266 | PMID 38558141 Get It

ImportanceFrontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, and standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers to trial recruitment and success, but no such tools are validated for FTLD.ObjectiveTo evaluate the reliability and validity of smartphone-based cognitive measures for remote FTLD evaluations.Design, Setting, and ParticipantsIn this cohort study conducted from January 10, 2019, to July 31, 2023, controls and participants with FTLD performed smartphone application (app)–based executive functioning tasks and an associative memory task 3 times over 2 weeks. Observational research participants were enrolled through 18 centers of a North American FTLD research consortium (ALLFTD) and were asked to complete the tests remotely using their own smartphones. Of 1163 eligible individuals (enrolled in parent studies), 360 were enrolled in the present study; 364 refused and 439 were excluded. Participants were divided into discovery (n = 258) and validation (n = 102) cohorts. Among 329 participants with data available on disease stage, 195 were asymptomatic or had preclinical FTLD (59.3%), 66 had prodromal FTLD (20.1%), and 68 had symptomatic FTLD (20.7%) with a range of clinical syndromes.ExposureParticipants completed standard in-clinic measures and remotely administered ALLFTD mobile app (app) smartphone tests.Main Outcomes and MeasuresInternal consistency, test-retest reliability, association of smartphone tests with criterion standard clinical measures, and diagnostic accuracy.ResultsIn the 360 participants (mean [SD] age, 54.0 [15.4] years; 209 [58.1%] women), smartphone tests showed moderate-to-excellent reliability (intraclass correlation coefficients, 0.77-0.95). Validity was supported by association of smartphones tests with disease severity (r range, 0.38-0.59), criterion-standard neuropsychological tests (r range, 0.40-0.66), and brain volume (standardized β range, 0.34-0.50). Smartphone tests accurately differentiated individuals with dementia from controls (area under the curve [AUC], 0.93 [95% CI, 0.90-0.96]) and were more sensitive to early symptoms (AUC, 0.82 [95% CI, 0.76-0.88]) than the Montreal Cognitive Assessment (AUC, 0.68 [95% CI, 0.59-0.78]) (z of comparison, −2.49 [95% CI, −0.19 to −0.02]; P = .01). Reliability and validity findings were highly similar in the discovery and validation cohorts. Preclinical participants who carried pathogenic variants performed significantly worse than noncarrier family controls on 3 app tasks (eg, 2-back β = −0.49 [95% CI, −0.72 to −0.25]; P &amp;lt; .001) but not a composite of traditional neuropsychological measures (β = −0.14 [95% CI, −0.42 to 0.14]; P = .32).Conclusions and RelevanceThe findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. Smartphone assessments should be considered as a complementary approach to traditional in-person trial designs. Future research should validate these results in diverse populations and evaluate the utility of these tests for longitudinal monitoring.
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Saloner, Rowan , Staffaroni, Adam M. , Dammer, Eric B. , Johnson, Erik C. B. , Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Lago, Argentina Lario , Webb, Julia D, Kramer, Joel H. , Li, Jingyao , Sivasankaran, Rajeev , Seyfried, Nicholas T. , Yokoyama, Jennifer S. , Grinberg, Lea T. , Ljubenkov, Peter A. , Brushaber, Danielle , Considine, Ciaran , Day, Gregory S. , Faber, Kelley , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hales, Chadwick M. , Huey, Edward D. , Kornak, John , Lee, Suzee, Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Paulson, Henry L. , Petrucelli, Leonard , Ramos, Eliana Marisa , Rascovsky, Katya, Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Vandebergh, Marijne , Rosen, Howie, Boxer, Adam L. , Casaletto, Kaitlin B. , Staffaroni, Adam M , Hansson, Oskar , Sivasankaran, Rajeev , Yokoyama, Jennifer , Spina, Salvatore , Grinberg, Lea , VandeVrede, Lawren , Brushaber, Danielle , Day, Gregory S , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Galasko, Douglas , Geschwind, Daniel , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Lapid, Maria I. , Litvan, Irene , Mendez, Mario , Pascual, Belen , Roberson, Erik , Snyder, Allison , Tartaglia, Maria Carmela , Vandebergh, Marijne , Boeve, Brad , Paulson, Henry L , Dammer, Eric B

Mayo Clinic

No container title available | March 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4103685/v1 | PMID 38585969 Get It

Abstract The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN, MAPT) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.